Scilex is covered by the following analysts:

Firm	Analyst Name
H.C. Wainright & Co.	Ram Selvaraju
Rodman & Renshaw	Elemer Pieros
D. Boral Capital	Jason Kolbert
Alliance Global Partners	James Molloy
Zacks	Brad Sorensen

May 2nd 2025
D. Boral Capital – SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at ASIPP
Read More About Scilex

April 2nd 2025
D. Boral Capital – Scilex Reports Full Year 2024 Results
Read More About Scilex

January 27th 2025
D. Boral Capital initiates coverage of SCLX with buy rating and PT of $22.00
Read More About Scilex

January 23rd 2025
Rodman and Renshaw reiterates buy rating for Scilex with PT $13
Read More About Scilex

January 21st 2025
Zacks reiterates buy rating for Scilex with PT $6.25
Read More About Scilex

December 20th 2024
Rodman and Renshaw reiterates buy rating for Scilex with PT $13
Read More About Scilex

December 10th 2024
Zacks reiterates buy rating for Scilex with PT $6.25
Read More About Scilex

October 21st, 2024
H.C.WAINWRIGHT & CO. Analyst reiterates buy rating with PT $7.00
Read More About Scilex

October 14th 2024
Rodman and Renshaw reiterates buy rating for Scilex with PT $13 as Scilex announces inline preliminary numbers.
Read More About Scilex

October 10th 2024
Zacks reiterates buy rating for Scilex with PT $5.50
Read More About Scilex

September 4th 2024
Zacks reiterates buy rating for Scilex with PT $5.50
Read More About Scilex

August 14th 2024
Zacks reiterates buy rating for Scilex with PT $5.50
Read More About Scilex

July 1st 2024
Rodman and Renshaw reiterates buy rating for Scilex with PT $13 as Scilex announces inline preliminary numbers.
Read More About Scilex

June 17th 2024
H.C.WAINRIGHT & CO. reiterates buy rating for Scilex with PT $7.00; states strategic financing alleviates overhang,
Read More About Scilex

June 14th 2024
B. Riley Securities reiterates buy rating for Scilex Holding with PT $4.00 citing strategic financing deal.
Read More About Scilex

June 12th 2024
Rodman and Renshaw reiterates buy rating for Scilex with PT $13 as major overhang is resolved.
Read More About Scilex

June 11th 2024
Zacks reiterates buy rating for Scilex with PT $5.00
Read More About Scilex

June 11th 2024
H.C.WAINRIGHT & CO. reiterates buy rating for Scilex with PT $7.00
Read More About Scilex

June 7th 2024
Rodman and Renshaw reiterates buy rating for Scilex with PT $13
Read More About Scilex

May 14th 2024
Zacks reiterates buy rating for Scilex with PT $4.50
Read More About Scilex

May 06th 2024
H.C.WAINRIGHT & CO. reiterates buy rating for Scilex with PT $8.00
Read More About Scilex

April 29th 2024
Rodman and Renshaw reiterate buy rating with PT of 13.00
Read More About Scilex

April 16th 2024
Rodman and Renshaw initiates reiterate buy rating for Scilex with PT $14
Read More About Scilex

April 8th 2024
Rodman and Renshaw initiates buy rating for Scilex with PT $14
Read More About Scilex

March 5th 2024
Zacks reiterates buy rating for Scilex with PT $4.50
Read More About Scilex

February 18th 2024
Zacks reiterates buy rating for Scilex with PT $4.75
Read More About Scilex

January 26th 2024
B. Riley Securities reiterates buy rating for Scilex Holding with PT $4.00
Read More About Scilex

January 23rd 2024
H.C.WAINRIGHT & CO. reiterates buy coverage for Scilex with PT $12
Read More About Scilex

December 4th 2023
H.C.WAINRIGHT & CO. reiterates buy coverage for Scilex
Read More About Scilex

November 24th 2023
B. Riley Securities reiterates buy rating for Scilex Holding with PT $4.00
Read More About Scilex

November 15th 2023
Zacks reiterates buy rating for Scilex with PT $4.75
Read More About Scilex

November 7th 2023
H.C.WAINRIGHT & CO. reiterates buy coverage for Scilex
Read More About Scilex

October 26, 2023
Zacks initiates coverage
Read More About Scilex

October 23, 2023
B. Riley Securities initiates coverage
Read More About Scilex

October 9th, 2023
H.C.WAINWRIGHT & CO. Analyst initiates coverage
Read More About Scilex

Disclaimer: Please note that any opinions, estimates or forecasts regarding the future performance of Scilex Holding Company’s business or stock price made by the analysts do not necessarily represent the views of Scilex Holding Company, Scilex Bio or its their management teams. Scilex is under no obligation to update this list or the information contained in the webpages to which it links, and thus such information may not be complete or up to date.